HOME >> BIOLOGY >> NEWS
'Sperm and germ'-fighting contraceptive enters trials

rm and germs, it must do so without hurting the friendly bacteria in a healthy vagina, like the lactobacilli, he explains. Also, it mustnt smell bad or taste bad or stain the sheets. And most importantly, it mustnt irritate sensitive vaginal tissues. BufferGel has met those standards both in animal trials and in extensive clinical safety trials, according to Cone.

For the new contraceptive efficacy trial, researchers at 10 sites in the United States are enrolling 1,000 women. Participants must be in a sexually active and monogamous relationship and at low risk for infection by sexually transmitted diseases. They must agree not to use other forms of contraception beyond that supplied by the study, and be willing to risk getting pregnant. Study participants will use a diaphragm with either BufferGel or a conventional spermicide.

In this trial, we want to achieve the highest possible level of protection, says Thomas Moench, medical director for ReProtect LLC. Were including a diaphragm because it places a discrete physical barrier over the cervix, significantly enhancing the protective actions of contraceptive microbicides.

Moench, formerly an assistant professor of infectious diseases at the Johns Hopkins Medical Institutions, originally created BufferGel with Cone. Hopkins and ReProtect LLC are developing BufferGel through a cooperative research agreement.

Researchers are also currently planning a larger trial to test BufferGels ability to block transmission of HIV and genital herpes. The trial is scheduled to take place through NIHs HIV Prevention Trials Network next year.


'"/>

Contact: Michael Purdy
mcp@jhu.edu
410-516-7906
Johns Hopkins University
3-Jan-2002


Page: 1 2

Related biology news :

1. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
2. UT Southwestern researchers discovery may lead to gene targets for new form of contraceptive
3. Oral contraceptives increase C-reactive protein, an infIammatory biomarker
4. The contraceptive plague
5. Newly found estrogen role in males might lead to contraceptive for men
6. New study shows oral contraceptive may be effective in treating severe form of premenstrual syndrome
7. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
8. Study suggests newer oral contraceptives may be less harmful for women smokers
9. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research
10. Images reveal how rotavirus - leading cause of diarrhea - enters cells
11. Proteomic research centers target bioterrorism agents, infectious diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... further extended its industry leading Biochemistry Services specifically targeting the rapidly growing ... and methods for the biochemical and biosimilar characterization , product-related impurity ...
Breaking Biology Technology:
Cached News: